BioWorld

March 14, 2007

View Archived Issues

Array Licenses TLR Program To VentiRx, Keeps Cancer Option

A week after closing a $26.6 million Series A financing to acquire Toll-like receptor (TLR) assets, VentiRx Pharmaceuticals Inc. licensed a preclinical TLR program from Array BioPharma Inc. (BioWorld Today) Read More

Virax Licenses Tech Patents For Transgene Immunotherapeutics

Read More

Alethia Enters Deal With Biosite For Ovarian Cancer Antibodies

Read More

Spectrum, FDA Formalize Plan For EOquin's Pivotal Studies

Read More

Other News To Note

Read More

Clinic Roundup

Read More